Check-Cap today announced that it has entered into definitive agreements with institutional investors for the purchase of 2,272,640 ordinary shares, at a purchase price of $1.10 per share.
| |
| [20-November-2017] |
| ISFIYA, Israel and BOSTON, Nov. 20, 2017 /PRNewswire/ -- Check-Cap (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that it has entered into definitive agreements with institutional investors for the purchase of 2,272,640 ordinary shares, at a purchase price of $1.10 per share. Additionally, the Company will issue to the investors unregistered, five-year warrants to purchase aggregate of up to 1,704,480 of its ordinary shares, at an exercise price of $1.25 per share, that are immediately exercisable. The Company will receive approximately $2.5 million gross proceeds at the closing of the offering and approximately $4.6 million total gross proceeds in the event that the warrants are exercised in full in cash. The offering is expected to close on or about November 22, 2017, subject to satisfaction of customary closing conditions. http://mma.prnewswire.com/media/509259/Check_Cap_Logo.jpg H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering. The Company intends to use the net proceeds from the offering to advance the ongoing clinical development of its C-Scan® system, and for general corporate purposes. The ordinary shares are being offered pursuant to a shelf registration statement (File No. 333-211065), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on July 11, 2016. A prospectus supplement and the accompanying prospectus relating to the ordinary shares will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. When available, copies of the prospectus supplement, and accompanying prospectus relating to the offering of the ordinary shares may also be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, New York 10022, by emailing placements@hcwco.com or by calling 646-975-6996. The warrants and the ordinary shares underlying the warrants are being offered and sold in a private placement and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and accordingly may not be offered or sold except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Check-Cap Check-Cap is a clinical-stage medical diagnostics company developing C-Scan®, the first capsule-based system for preparation-free colorectal cancer screening. Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation. The C-Scan system is currently not cleared for marketing in any jurisdiction. Legal Notice Regarding Forward-Looking Statements This press release contains “forward-looking statements.” Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: risks associated with market conditions and the satisfaction of customary closing conditions related to the offering. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the “Special Note On Forward-looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Investor Contacts Meirav Gomeh-Bauer View original content:http://www.prnewswire.com/news-releases/check-cap-ltd-announces-25-million-registered-direct-offering-300559306.html SOURCE Check-Cap Ltd. | ||
Company Codes: NASDAQ-SMALL:CHEK, Frankfurt:7CC |
